Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2005-01-21
2011-11-08
Burkhart, Michael (Department: 1633)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S320100
Reexamination Certificate
active
08053232
ABSTRACT:
The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells. The methods and compositions of the present invention can be used in gene therapy for correction of SERPINA1 disorders such as AAT deficiency.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 4981783 (1991-01-01), Augenlicht
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5589377 (1996-12-01), Lebkowski et al.
patent: 5599672 (1997-02-01), Liang et al.
patent: 5616326 (1997-04-01), Spibey
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5700470 (1997-12-01), Saito et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 5747072 (1998-05-01), Davidson et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5789390 (1998-08-01), Descamps et al.
patent: 5820868 (1998-10-01), Mittal et al.
patent: 5837484 (1998-11-01), Trempe et al.
patent: 5843742 (1998-12-01), Natsoulis et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5869037 (1999-02-01), Crystal et al.
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5877011 (1999-03-01), Armentano et al.
patent: 5882874 (1999-03-01), Fisher
patent: 5885808 (1999-03-01), Spooner et al.
patent: 5891690 (1999-04-01), Massie
patent: 5919676 (1999-07-01), Graham et al.
patent: 5922576 (1999-07-01), He et al.
patent: 5928944 (1999-07-01), Seth et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 5952221 (1999-09-01), Kurtzman et al.
patent: 5962311 (1999-10-01), Wickham et al.
patent: 5962313 (1999-10-01), Podsakoff et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6013487 (2000-01-01), Mitchell
patent: 6025192 (2000-02-01), Beach et al.
patent: 6083702 (2000-07-01), Mitchell et al.
patent: 6146877 (2000-11-01), Fisher
patent: 6235310 (2001-05-01), Wang et al.
patent: 6245520 (2001-06-01), Wang et al.
patent: 6245747 (2001-06-01), Porter et al.
patent: 6255071 (2001-07-01), Beach et al.
patent: 6280978 (2001-08-01), Mitchell et al.
patent: 7094399 (2006-08-01), Otto
patent: 7399753 (2008-07-01), Mitchell
patent: 2006/0094110 (2006-05-01), McGarrity
patent: 2006/0134658 (2006-06-01), Garcia-Blanco
patent: 2006/0154257 (2006-07-01), Mitchell
patent: 2006/0160182 (2006-07-01), McGarrity
patent: 2006/0172381 (2006-08-01), McGarrity
patent: 2006/0177933 (2006-08-01), Puttaraju
patent: 2006/0194317 (2006-08-01), Puttaraju
patent: 2006/0246422 (2006-11-01), Mitchell
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/10134 (1989-11-01), None
patent: WO 89/12690 (1989-12-01), None
patent: WO 98/11241 (1998-03-01), None
patent: WO 98/42315 (1998-10-01), None
patent: WO 99/43844 (1999-09-01), None
patent: WO 99/49898 (1999-10-01), None
patent: WO 00/09734 (2000-02-01), None
patent: WO 00/09734 (2000-03-01), None
patent: WO 00/55174 (2000-09-01), None
patent: WO 00/58350 (2000-10-01), None
patent: WO 01/46386 (2001-06-01), None
patent: WO 02/08242 (2002-01-01), None
patent: WO 02/16419 (2002-02-01), None
Scheidner, G. et al., “Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity”, 1998, Nat. Genetics, vol. 18: pp. 180-183.
Stoll, S. et al., “Epstein-Barr Virus/Human Vectors Provides High-Level, Long-Term Expression of alpha1-Antitrypsin in Mice”, 2001, Mol. Ther., vol. 4: pp. 122-129.
Elbashir, S. et al., “RNA interference is mediated by 21 and 22 nucleotide RNAs”, 2001, Genes & Dev., vol. 15: pp. 188-200.
Crystal, R., “Alpha1-Antitrypsin Deficincy, Emphysema, and Liver disease”, 1990, J. Clin. Invest., vol. 85: pp. 1343-1352.
U.S. Appl. No. 09/648,310, filed Aug. 25, 2000, Fisher et al.
United States Patent Publication 2001/0014734 by Fisher published Aug. 16, 2001 and entitled “Progression elevated gene-3 and uses thereof.”
Rubanyi G.M. The future of human gene therapy Mol Aspects of Medicine 2001 22:113-142.
Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res 2001;61(11):4405-4413.
Perrais M, Pigny P, Ducourouble MP, Petitprez D, Porchet N, Aubert JP, Van Seuningen I. Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. J Biol Chem 2001;276(33):30923-30933.
Su Z, Shi Y, Fisher PB. Rattus norvegicus progression elevated gene-3 protein (Peg-3) gene, promoter region. Genbank Accession No. AF351130. Submitted Feb. 20, 2001.
Tanaka M, Inase N, Miyake S, Yoshizawa Y. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anticancer Res 2001;21(1A):291-194.
Xie X, Zhao X, Liu Y, Young CY, Tindall DJ, Slawin KM, Spencer KM. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther 2001;12(5):549-561.
Adachi Y, Reynolds PN, Yamamoto M, Grizzle WE, Overturf K, Matsubara S, Muramatsu T, Curiel DT. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res 2000;60(16):4305-4310.
Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 2000;1(1):31-38.
U.S. Appl. No. 09/648,310 by Fisher et al., filed Aug. 25, 2000, and entitled “Progression suppressed gene 13 (PSGen13) and uses thereof.”
Hu, R.-M et al., Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning Proc Natl Acad Sci USA 2000 97(17):9543-9548.
Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y. Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. Intl J Cancer 2000;85(5):716-719.
O'Keefe et al., Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000;45(2):149-157.
Perrais M, Pigny P, Ducourouble MP, Petitprez D, Porchet N, Aubert JP, Van Seuningen I.Homo sapiensmucin 4 (MUC4) gene, promoter sequence and partial cds. GenBank Accession No. AF241535. Submitted Mar. 3, 2000.
Ye et al., “Homo sapiensHSP C280 mRNA, Partial CDS; Human partial CDS from stem cells,” EMBL #AF161398, Feb. 1, 2000.
Zhang Q.-H et al., Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells Genome Res 2000 10:1546-1560.
Case SA, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM. Stable transduction of quiescent CD34(+)CD38(−) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 1999;96(6):2988-2993.
Connelly S. Adenoviral vectors for liver-directed gene therapy. Curr Opin Mol Ther 1999;1(5):565-572.
Gopalkrishnan RV, Christiansen KA, Goldstein NI, DePinho RA, Fisher PB. Use of the human EF-1alpha promoter for expression can signifi
Cote Colette
Garcia-Blanco Mariano A.
Mansfield S. Gary
McGarrity Gerard J.
Mitchell Lloyd G.
Burkhart Michael
Sira, Esq. Serge
VIRxSYS Corporation
VIRxSYS Corporation
LandOfFree
Correction of alpha-1-antitrypsin genetic defects using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Correction of alpha-1-antitrypsin genetic defects using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Correction of alpha-1-antitrypsin genetic defects using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300286